Latest News for 03/2020
03 Mar 2020
Two Life Sciences academics who are helping transform lives with their work on major diseases including Parkinson’s and neglected tropical diseases such as malaria have been elected Fellows of the Royal Society of Edinburgh (RSE). The RSE is Scotland’s national academy, focused on delivering its mission of `knowledge made useful’. Fellows are elected in recognition of their impact in improving the world around them.
11 Jul 2019
Researchers from the Drug Discovery Unit have been awarded the “Project of the Year 2018” from Medicines for Malaria Venture (MMV) for their discovery work on potential new drugs for malaria. The annual award goes to the scientific partners involved in that year’s most exciting project from the MMV portfolio. MMV is the world’s leading product development partnership (PDP) for discovering and developing new effective and affordable medicines to treat malaria.
12 Feb 2019
Researchers in the Wellcome Centre for Anti-Infectives Research (WCAIR) have been awarded £700,000 to investigate whether bacteria and other natural products found in the Amazon hold the key to developing new drugs for neglected tropical diseases. The team led by Professor Kevin Read will work with colleagues in Brazil to identify novel drug targets and develop new therapies for visceral leishmaniasis and Chagas’ disease.
25 Jul 2018
A new preclinical candidate drug with the potential to treat visceral leishmaniasis, one of the world’s major neglected diseases, has been discovered through a close collaboration between the University of Dundee, GSK and Wellcome.
14 Jun 2017
Ten partnership building projects, including two from the School, have been awarded internal Pump-Priming Funding from the University’s SFC GCRF funding allocation. The aim of the competition, coordinated by Research & Innovation Services (RIS), is to enhance our ability to respond to funding opportunities under the Global Challenges Research Fund (GCRF).
27 Mar 2017
Antimicrobial resistance is one of the greatest threats to global human and animal health – the O’Neill Report published last year stated that, unless we take urgent action, it will be directly responsible for over 10 million deaths by 2050, more than deaths from cancer or deaths from diabetes, road traffic accidents and cholera combined. A crucial part of the solution is to find new antibiotics to tackle bacterial infections and replace existing treatments which have become ineffective, often through over
17 Jan 2017
The School hosted the 45th Scottish Regional Meeting of the Royal Society of Chemistry (RSC) Organic Division on 11th January. The conference is traditionally called the "Perkin Meeting”, and it brings together all the organic chemists in Scotland for a 1 day meeting every year. It includes the Organic Chemistry Departments of Edinburgh, Glasgow, Strathclyde, Herriot-Watt, St Andrews, Aberdeen and Dundee.
30 Jun 2015
The Drug Discovery Unit at the University of Dundee has been awarded “Project of the Year, 2014” by the not-for-profit organisation, Medicines for Malaria Venture for their work on the new potential anti-malaria compound “DDD107498 – The Compound with Muscle”. The discovery of the compound was recently published in the journal Nature and has been selected as a preclinical candidate by MMV and recently partnered with the pharmaceutical company Merck Serono.
17 Jun 2015
The details of the discovery, properties and mechanism of action of a novel antimalarial compound, DDD107498, have been published in the journal Nature. DDD107498 has the potential to treat malaria patients in a single dose, including those with malaria parasites resistant to current medications, and help reduce the transmission of the parasite. The compound was identified through a collaboration between the University of Dundee’s Drug Discovery Unit (DDU) and Medicines for Malaria Venture (MMV).
06 Feb 2014
A significant milestone in the development of a potential new antimalarial medicine has been reached by scientists at the University of Dundee, in partnership with the Medicines for Malaria Venture (MMV). A compound developed in the Drug Discovery Unit at Dundee has been selected by MMV, following a positive recommendation by MMV’s Expert Scientific Advisory Committee, to enter preclinical development.